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Introduction
New medicines have therapeutic beneﬁts, but also are potentially
harmful for subgroups of patients. Longer-term safety issues
often only become apparent during postmarketing surveillance
and have in some cases led to key decisions to withdraw products
over safety concerns, e.g., Vioxx and Lotronex, the latter subse-
quently being made available again in response to patient pres-
sure through a restricted access drug distribution program. The
issue of harms and beneﬁts is very visible to licensing bodies and
the public; however, decision-making in this context lacks trans-
parency and consistency, and appears to neglect the application
of modeling and other techniques that have proven useful in
cost-effectiveness analyses to address uncertainty around out-
comes similar to those used in beneﬁt–harm analyses. Indeed, as
this ﬁeld develops, it is becoming clear that beneﬁt–harm analysis
holds great potential as a tool for informing decision-making by
both regulatory and health technology assessment bodies that are
faced with an increasing number of situations in which there is a
trade-off between positive and negative health effects. Develop-
ments in this ﬁeld are discussed. We follow the convention of
referring to these trade-offs as “beneﬁt risk analysis,” although
we share Aaronson’s view [1] that beneﬁt–harm is a more appro-
priate description.
Trading Beneﬁts and Risks
Methods for quantifying incremental beneﬁts and risks have been
described in the literature and reviewed by Cross and Garrison
[2] and by Mussen et al. [3]. We focus on three. In the ﬁrst
example discussed here, Briggs and Levy [4] use data collected by
Lynd and O’Brien [5] to present a very simple way of how one
might trade-off beneﬁts and risks of two interventions, unfrac-
tionated heparin and enoxaparin, for the treatment of deep vein
thrombosis (DVT) after major trauma. The basic assumption is
that as the numbers of patients in the two arms of the trial are
broadly equivalent, the absolute numbers of events that occurred
can be compared to assess whether the extra beneﬁts are worth
the extra risks. One product is producing more beneﬁts, but also
potentially more risks (Table 1).
Is that a good trade-off? When these positive and negative
effects are placed on a cost-effectiveness plane that illustrates the
joint distribution of risk of a major bleed and the probability of
a reduction in DVT (Fig. 1), the incremental risk–beneﬁt ratio
is approximately one-third; in other words, if the beneﬁt of
averting a proximal DVT is valued at one-third or more than the
consequences of an adverse event, then the technology should be
used. And so, this represents a simple quantitative approach to
deﬁning a risk–beneﬁt acceptability threshold. The decision-
maker has to decide the positive and negative values, respectively,
of the beneﬁt “event” and the risk “event” and his or her will-
ingness to trade one for the other.
The second approach uses quality-adjusted life-years
(QALYs) to create a “common currency” for comparing beneﬁts
and risks. The simplest version of this approach involves adding
up positive and negative QALYs [6]. As shown in Table 2, the
means of the expected beneﬁts and the expected negative effects
(measured in QALYs) were netted to generate an overall popu-
lation effect in terms of the incremental net health beneﬁt or
potential net beneﬁt of the drug. In this case, the authors posi-
tioned the article to demonstrate the potential of using value of
information approaches within a licensing context (i.e., to con-
sider when safety data should be collected alongside use of the
product, rather than in advance of its use) and the merit of
considering QALYs as an appropriate measure of absolute health
effects. The authors noted that although they had combined
positive and negative QALYs on a 1:1 basis in their example,
there was no need for decision-makers to do this. Negative
QALYs could be given a higher weight if licensing bodies
attached a higher value to avoiding adverse effects than to achiev-
ing health gain. Nevertheless, such a judgment would be explicit.
Another study using QALYs to inform beneﬁt–risk assess-
ments was undertaken by Lynd [7] in a simulation analysis of
Vioxx compared to naproxen. The ﬁrst step was to attach nega-
tive (“disutility”) incremental QALY values for, and durations to,
the events that might occur, ranging from dyspepsia to mycardial
infarction. A discreet event simulation of 10,000 patients then
produced the numbers of the different types of adverse events
that occurred in each treatment arm. Focusing only on side
effects, the simulation demonstrated that, on the assumption that
the drugs were of equal efﬁcacy, there was a 96% chance that the
incremental net beneﬁt of Vioxx as measured by QALYs was
positive relative to the use of naproxen, calling into question
whether the evidence that led to the removal of Vioxx from the
market had been put into an appropriate context. Again,
decision-makers may choose to give different weights to QALYs
arising from different side effects. Such judgments can be made
explicitly.
A variant of the use of QALYs to inform beneﬁt–risk assess-
ments is the use of “relative value adjusted life years” or
RVALYs. In a second analysis, Lynd et al. [8] quantiﬁed incre-
mental net health beneﬁts of alosetron, originally indicated for
irritable bowel syndrome (IBS), withdrawn from the market, and
subsequently re-introduced with a restricted indication, using
preference weights derived using conjoint analysis, generating
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a measure of health beneﬁt that the authors called RVALYs. The
preference weights (relative values of different beneﬁts and side
effects) were obtained from 565 IBS patients using a discrete
choice experiment. By combing the preferences attached to the
events with the probabilities that these events might occur,
according to the original clinical trial data, they were able to
calculate a net effect of 34.1 RVALYs gained per 1000 patients
relative to placebo, comprising 34.9 RVALYs of beneﬁt and -0.8
RVALYs of disutility. A probability sensitivity analysis indicated
that if positive and negative RVALYs were regarded as equally
desirable by decision-makers (a 1:1 trade-off), then there was a
99% chance of alosteron having a positive incremental net
beneﬁt. The RVALY approach of combining negative and posi-
tive health effects showed on the available data and a 1:1 trade-
off that there is an overall positive health effect associated with
using this intervention. Again, decision-makers could treat some
RVALYs as more important than others and use weightings other
than a 1:1 trade-off. This framework would enable such deci-
sions to be explicit and the weightings to be transparent.
The third method is to inform decision-makers about
patients’ willingness to trade the beneﬁts and risks associated
with treatment. This goes beyond the patient preferences incor-
porated in the RVALY variant of QALYs we considered previ-
ously to focus only on patient willingness to trade real risks
against clinically realistic improvements in health. Not unsurpris-
ingly we ﬁnd that patients who can expect to gain the most are
more willing to put up with the risk of a serious adverse event.
Johnson et al. [9] use conjoint or stated preference techniques to
evaluate women’s willingness to accept adverse events from the
use of hormone therapy in return for a reduction in vasomotor
symptoms. In Figure 2, we see the maximum acceptable risks for
heart attack by treatment beneﬁt and it is shown that those who
can gain most are most willing to accept the risk of heart attack.
This study is consistent with accumulating evidence associating
subgroups of patients expecting larger anticipated beneﬁt with
increasing maximum acceptable risk of a given side effect. So,
despite adverse events occurring fairly consistently across all
patient groups, some sub-groups will get more beneﬁt from the
treatment than others, and from the perspective of a licensing
decision, it is those patients for whom the product should be
made available. Again, decision-makers can attach their own
values to potential beneﬁts and risks. Nevertheless, an under-
standing of patient perception of beneﬁt and risk is likely to assist
in any such weighting by decision-makers.
Multicriteria Decision Analysis
Finally, to multi-criteria decision analysis (MCDA), which offers
a mechanism to structure decision-making such that it is very
clear how the decision was made [3]? This is not a method to
bring quantitative information inside from outside as with our
three methods discussed previously. Rather, this technique helps
decision-makers be more explicit in their own deliberations, to
Table 1 Summary of events from a clinical trial of low-dose unfraction-
ated heparin versus enoxaparin for the prevention of deep vein throm-
bosis after major trauma
Event
Numbers experiencing an event*
Unfractionated heparin Enoxaparin Difference†
Beneﬁts
Distal DVT 40 32 -8
Proximal DVT 20 8 -12
Risks
Major bleeds 1 5 +4
*Focus on numbers (rather than probabilities) ignores the slight imbalance between arms of
the trial low-dose unfractionated heparin, n = 136; enoxaparin, n = 129).
†Negative numbers are events avoided, positive numbers are excess events [5].
DVT, deep vein thrombosis.
Figure 1 Proximal deep vein thrombosis (DVT)
versus major bleed: (m = threshold ratio) shown as
a joint distribution of risk and beneﬁt on a cost-
effectiveness plane. Results of the second-order
Monte Carlo simulation of the DVT trial plotted
on the risk–beneﬁt plane: the incremental prob-
ability of a DVT (DB) versus the incremental prob-
ability of major bleed (DR). Lines extending from
the origin into the NE quadrant represent different
risk–beneﬁt threshold values (m).The • marks the
point estimate of the risk–beneﬁt ratio (if DVTs
and major bleeds are valued equally, the risk–
beneﬁt ratio = 1) [5].
Table 2 Estimated aggregate incremental net health beneﬁts [6])
Mean Range
Expected beneﬁt per treated patient (QALY) 0.20 0.05–0.36
Expected risks (harms) per treated patient
(QALY)
(0.05) (0.08)–(0.03)
Difference: INHB (net QALY per patient) 0.15 (0.03)–0.33
Population parameters
Total: 300,000,000
Annual cohort entering treatment: 150,000
Aggregate annual INHB
Beneﬁt (in QALYs) 30,000 7,500–54,000
Risk (in QALYs) (7,500) (12,000)–(4,500)
Difference (annual INHB) 22,500 (4,500)–49,500
Note: Hypothetical assumptions and calculations. Numbers in parentheses are negative
quantities.
INHB, incremental net health beneﬁt; QALY, quality-adjusted life-year.
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understand the importance (high or low) they are attaching to
particular factors. This enables them to: better understand which
factors are driving their decisions; change their thinking if the
results do not make intuitive sense to them when their implicit
assumptions are made clear to them; and explain to the public
the basis on which decisions have been made. It is particularly
important in regulatory review or health technology assessment,
as it lends consistency and transparency, which is often lacking,
in cases where there are negative and positive health effects. Of
course, there may be concerns that the use of MCDA will make
decision-making too complex or too mechanistic, removing the
element of deliberation [10]. In adopting this approach, regula-
tory review committees and health technology assessment com-
mittees would be advised to include modeling experts who can
guide the application of models that mathematically analyze
complex trade-offs between different criteria and that are neces-
sary to provide structure to the deliberative decision-making
process that is required. The objective, however, is not to replace
the judgment of experts but to make it better informed, more
considered, more likely to be “right” and, whatever decision is
made, easier to explain to patients, clinicians, payers, and phar-
maceutical companies.
Closing Remarks
We are now at a point where decision support tools and tech-
niques that incorporate combined positive and negative health
effects, and weighting systems based on absolute measures of
health have demonstrated utility in informing regulatory
decision-making. These tools potentially offer decision-makers
an opportunity to be more consistent and transparent. Neverthe-
less, decision-makers themselves must understand and accept the
risk–beneﬁt analysis techniques that are being applied to generate
these analyses if they are to accept or reject assumptions that
support the use of an intervention in speciﬁc circumstances. On
a cautionary note, it should be recognized that this ﬁeld is in its
infancy and many more studies of original data are required to
ascertain how beneﬁt–risk analyses can lead to better health-care
decisions.
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